

Overview: ICCB-L/NSRB Screening Facility User Agreement for Small Molecule Screening Projects

There are two different ICCB-L/NSRB User Agreements, one for small molecule screeners and one for RNAi screeners. Small molecule user agreements apply only to small molecule screening projects and data; RNAi agreements apply only to RNAi projects and data. Screeners carrying out both small molecule and RNAi screening projects at ICCB-L/NSRB must sign both small molecule and RNAi user agreements. All Users from the same research group must choose the same data sharing level, with the decision to be made by the principal investigator of that group.

The right of users to perform screens at ICCB-L/NSRB is solely at the discretion of the ICCB-L/NSRB Directors and the ICCB-L and NSRB scientific advisory committees. By signing the agreement, all users agree to deposit annotated screening data into Screensaver, to hold in confidence all unpublished data that they access about other screens via Screensaver, and to allow ICCB-L/NSRB to use their data for quality control improvements and statistical analysis.

This agreement requires each small molecule screener to choose a level of pre-publication data sharing: Level 1, Level 2, or Level 3. The main points regarding each level are summarized below. Although sharing small molecule screening data prior to publication is not required of ICCB-L/NSRB screeners, we strongly recommend it and encourage you to share your data at Level 1 or Level 2. In our experience, the benefits of sharing small molecule primary screen results before publication within the community of ICCB-L/NSRB screeners far outweigh any potential risks. We believe that the new ICCB-L/NSRB policies are fair and will meet the requirements of NIH data sharing guidelines. Further, we have been advised that sharing data within the context of Screensaver does not constitute public disclosure for patent purposes. However, individuals may wish to consult with their own patent counsel as appropriate.

Regardless of the level of participation chosen by a screener, all annotated small molecule screening data must be deposited into Screensaver in a timely manner, as it is obtained. Upon publication, data from screens conducted at ICCB-L/NSRB will be made available to all Screensaver users. The data sharing agreement (and access to Screensaver) will expire two years from the date of execution. However, screeners who wish to retain access to Screensaver may renew their data sharing agreement. Screening data will be shared at Level 1 and 2 beginning two years after completion of each screen, as defined jointly by each screen's principal investigator and ICCB-L/NSRB staff. We will also work with screeners to format post-publication data for entry into the PubChem database (<http://pubchem.ncbi.nlm.nih.gov/>), which is publicly available.

Pre-publication sharing options for small molecule screen data:

Level 3: Screening data are not shared with other Screensaver users, unless they are designated as collaborators by the lead screener or PI of the screen. Screeners automatically become Level 3 users when their projects are accepted for piloting or screening at ICCB-L/NSRB. Level 3 Users have access only to basic information about ICCB-L/NSRB compound and RNAi libraries, information about their own screening project(s), and data from published screens.

Level 2: Only data related to Overlapping Hits are shared among Level 2 users. Level 2 users will also have access to Overlapping Hit information from Level 1 screens. An Overlapping Hit is defined as a compound that has been annotated as a positive in another screen. Data that will be shared for each Overlapping Hit include:

- titles and brief general descriptions of other screens that also scored the compound as a positive
- identity and contact information for investigator(s) associated with screens that have Overlapping Hits
- summary experimental and data analysis protocols for screens that have Overlapping Hits
- whether the Overlapping Hit was chosen as a cherry pick, and whether the cherry pick was confirmed as a positive in those screens

Level 1: All data are shared among Level 1 users. Level 1 users will also have access to Overlapping Hit information from Level 2 screens.

Signed forms should be sent to Su Chiang at the address below. Electronic copies are preferred if possible.

Su L. Chiang, Ph.D.
Seeley Mudd 604, Harvard Medical School
250 Longwood Avenue
Boston, MA 02115 USA
su_chiang@hms.harvard.edu
617-432-5237
617-432-6424 (fax)